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osting by EAbstract Nutritional genetics is considered as the combination of nutrigenomics and nutrigenetics.
Nutrigenomics is establishing the effects of ingested nutrients and other food components on gene
expression and gene regulation. It will also determine the individual nutritional requirements based
on the genetic makeup of the person (personalized diet) as well as the association between diet and
chronic diseases which will help to understand the etiologic aspects of chronic diseases such as can-
cer, type-2 diabetes, obesity and cardiovascular disease (CVS). Nutrigenetics on the other hand
identiﬁes how the genetic makeup of a particular individual co-ordinates his or her response to var-
ious dietary nutrients. It also reveals why and how people respond differently to the same nutrient.
The present review will focus upon interaction of genetic background and diet with regard to devel-
opment of such life threatening chronic conditions as obesity, cardiovascular disease (CVD), and
cancer that are responsible for the majority of deaths in developed Western countries.
 2011 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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Nutritional genetics is not a single ﬁeld, but is considered as
the combination of two-nutrigenomics and nutrigenetics [1].
1.1. Nutrigenomics
Nutrigenomics is establishing the effects of ingested nutrients
and other food components on gene expression and gene reg-
ulation, i.e., to study diet-gene interaction in order to identify
the dietetic components having beneﬁcial or detrimental health
effects [1,2]. It will also determine the individual nutritional
requirements based on the genetic makeup of the person (per-
sonalized diet) as well as the association between diet and
chronic diseases which will help to understand the etiologic as-
pect of chronic diseases such as cancer, type-2 diabetes, obesity
and cardiovascular disease (CVS) [2]. Nutrigenomics will also
identify the genes involved in physiological responses to diet
and the genes in which small changes, called polymorphisms,
may have signiﬁcant nutritional consequences and the inﬂu-
ence of environmental factors on gene expression [3].
1.2. Nutrigenetics
Nutrigenetics on the other hand identiﬁes how the genetic ma-
keup of a particular individual co-ordinates his or her response
to various dietary nutrients. It also reveals why and how peo-
ple respond differently to the same nutrient [4].
Together these two approaches promise to deliver a critical
part of the scientiﬁc knowledge needed to understand how diet
affects the individual humans [1] and eventually nutrigenomics
will lead to evidence-based dietary intervention strategies for
restoring health and ﬁtness and for preventing diet-related dis-
ease [5].
2. Gene diet disease interaction
2.1. Nutrigenetic diseases
Ninety seven percent of the genes have known to be associated
with human diseases result in monogenic diseases. Modifying
the dietary intake can prevent some monogenetic diseases [6],
e.g., in phenylketonuria (PKU) food containing the amino acid
phenylalanine, including high protein food such as ﬁsh, chick-en, eggs, milk, cheese, dried beans, nuts, and tofu must be
avoided. In case of defective aldehyde dehydrogenase enzyme,
alcohol must be avoided. Patients having galactosemia (lack of
a liver enzyme to digest galactose) should avoids diets which
contain lactose or galactose, including all milk and milk
products while in case of lactose intolerance (shortage of the
enzyme lactase) patients should avoid milk and milk products
[7].
2.2. Nutrigenomic diseases
Diseases and conditions that are known to have genetic and/or
nutritional components are candidates for nutrigenomic
studies to determine whether dietary intervention can affect
the outcome. Differences in genetic makeup or genotype are
factors in gastrointestinal cancers, other gastrointestinal
conditions or digestive diseases, inﬂammatory diseases, and
osteoporosis. Nutrient imbalances are factors in aging, alco-
holism/substance abuse, behavioral disorders, cancer, cardio-
vascular disease (CVD), chronic fatigue, deafness, diabetes,
immune disorders, macular degeneration, multiple sclerosis,
neurological disorders, osteoporosis, Parkinson’s disease and
stroke [7]. Diseases that are known to involve in the interac-
tions between multiple genetic and environmental factors such
as diet include, many cancers, diabetes, heart disease, obesity
and some psychiatric disorders [7].
Therefore, both disciplines aim to unravel diet/genome
interactions; however, their approaches and immediate goals
are distinct. Nutrigenomics will unravel the optimal diet from
within a series of nutritional alternatives, whereas nutrigenetics
will yield critically important information that will assist
clinicians in identifying the optimal diet for a given individual,
i.e., personalized nutrition [8].
The following ﬁve tenets of nutritional genomics serve as a
conceptual basis for understanding the focus and promise of
this emerging ﬁeld [3]:
1. Under certain circumstances and in some individuals, diet
can be a serious risk factor for a number of diseases.
2. Common dietary chemicals can act on the human genome,
either directly or indirectly, to alter gene expression or
structure.
3. The degree to which diet inﬂuences the balance between
healthy and disease states may depend on a person’s genetic
makeup.
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variants) are likely to play a role in the onset, incidence,
progression, and/or severity of chronic diseases.
5. Dietary intervention based on the knowledge of nutritional
requirements, nutritional status, and genotype (i.e., person-
alized nutrition) can be used to prevent, mitigate, or cure
chronic disease.3. Single nucleotide polymorphism (SNP)
Most of the genes have small sequence differences – polymor-
phisms – that vary among individuals. Single nucleotide
polymorphisms (SNPs) are the most common type of variation
[4].
The single nucleotide polymorphisms consortium is map-
ping polymorphic regions of the genome that control individ-
ual phenotypic differences among the human population. The
importance of this genetic variation to the varying needs for
and physiological responses to the particular nutrients was
stated by Ames [9]. Missense single nucleotide polymor-
phisms occur about 1 in every 1000 bases in expressed genes,
so one expects that there will be many more polymorphisms
to be found in micronutrient and dietary studies. Speciﬁc ge-
netic polymorphisms in human populations change their met-
abolic response to diet and inﬂuence the risk patterns of
disease as SNPs are similar to variations in a recipe. Each
gene is a recipe for a speciﬁc protein or group of proteins that
either regulate biological functions or serve as structural build-
ing blocks for tissues (e.g., collagen). Some SNPs change the rec-
ipe for the gene so that either a different quantity of the protein
is produced or the structure of the proteinmolecule is altered [3].
These genetic polymorphisms lead to alteration of the
response to the dietary components by inﬂuencing absorp-
tion and metabolism. Epigenetic events can induce changes
in DNA methylation pattern and thus inﬂuencing over all
gene expression that can be modiﬁed in response to the
food components. Many dietary constituents affect
post translation events and many account for at least part
of the variation in response to the dietary components [10].
One of the best-described examples of the effect of SNPs
is the relationship between folate and the gene for MTHFR
– 5,10-methylenetetrahydrofolate reductase. MTHFR has a
role in supplying 5-methylenetetrahydrofolate, which is neces-
sary for the re-methylation of homocysteine to form methio-
nine. Methionine is essential to many metabolic pathways
including production of neurotransmitters and regulation of
gene expression. Folate is essential to the efﬁcient functioning
of this MTHFR. There is a common polymorphism in the gene
for MTHFR that leads to two forms of protein: the wild type
(C), which functions normally, and the thermal-labile version
(T), which has a signiﬁcantly reduced activity. People with two
copies of the wild-type gene (CC) or one copy of each (CT)
appear to have normal folatemetabolism.Thosewith two copies
of the unstable version (TT) and low folate accumulate homo-
cysteine and have less methionine, which increases their risk of
vascular disease and premature cognitive decline [11].
4. Nutrigenomics and chronic disease
The present review will focus upon interaction of genetic back-
ground and diet with regard to development of such life threat-ening chronic conditions as obesity, CVD, and cancer that are
responsible for the majority of deaths in developed western
countries [3]. The nature of these interactions is indeed very
complex.
4.1. Nutrigenomics and obesity
Obesity is the commonest nutrition-related disorder and is the
core element of a group of metabolic abnormalities (metabolic
syndrome) which also commonly includes insulin resistance
and hyperinsulinemia, hypertension, impaired glucose toler-
ance, and noninsulin-dependent diabetes mellitus [12]. Also
obesity and associated metabolic anomalies dramatically in-
crease the risk of developing a variety of chronic diseases
including CVD and cancer [13,14]. However, individual sus-
ceptibility to obesity strongly depends on the genetically deter-
mined patterns of energy balance regulation [15].
Multiple polymorphic genes encoding central and periphe-
ral determinants of energy intake and expenditure have been
revealed over the past decade. Food intake control may be af-
fected by polymorphisms in the genes encoding taste receptors
and a number of peripheral signaling peptides such as insulin,
leptin, ghrelin, cholecystokinin, and corresponding receptors
[15]. Polymorphic central regulators of energy intake include
hypothalamic neuropeptide Y, agouti-related protein, melano-
cortin pathway factors, CART (cocaine- and amphetamine-
regulated transcript), some other neuropeptides, and receptors
for these molecules. Potentially important polymorphisms in
the genes encoding energy expenditure modulators (alpha-
and beta-adrenoceptors, uncoupling proteins, and regulators
of adipocyte growth and differentiation) are also known [15].4.2. Nutrigenomics and CVD
CVD is the primary diet-related chronic disease of the modern
time and the inﬂammation is emerging as underlying many
chronic disorders including CVD. CVD can be characterized
as a group of multifactorial conditions associated with obesity,
atherosclerosis, hypertension, and thrombosis. All of these
pathologic entities are known to be closely related to both ge-
netic factors and environmental inﬂuences. Diet is considered
as one of the environmental inﬂuences and a strong relation-
ship between diet composition and CVD risk is well estab-
lished [16–19].
Obesity per se is a major cardiovascular risk factor, thus
polymorphic genes involved in energy balance control cer-
tainly provide ‘‘favorable’’ or ‘‘unfavorable’’ background for
the development of CVD [15].
Atherosclerosis constitutes the key element in the pathogen-
esis of CVD and it can be regarded as a complex combination
of lipid transport and metabolism disorder with chronic
inﬂammation [16,20]. Permanently elevated plasma levels of
total cholesterol, LDL cholesterol, and triglycerides predispose
to the development of atherosclerotic plagues, whereas in-
creased high density lipoprotein (HDL) cholesterol levels ap-
pear to be protective [15]. Genetic variation in genes
encoding for apolipoproteins, some enzymes and hormones
can alter individual sensitivity to develop the cardiovascular
diseases. Some of these variants are susceptible for dietary
intervention, for example: Individuals with the E4 allele in
the apolipoprotein E gene show higher low-density lipopro-
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fat intake compared with those with the other (E1, E2 and
E3) alleles receiving equivalent amounts of dietary fat [21].
ApoA1 is primarily found in the HDL particles. AG to A
transition in the promoter of APOA1 gene is associated with
increased HDL-cholesterol concentration but the results across
studies are not consistent [22]. Ordovas et al. [23] found that
the allele A was associated with the decreased serum HDL lev-
els. The genetic effect was reversed, however, in women who
ate more polyunsaturated fatty acids (PUFA). In men, this
type of fat effect was signiﬁcant when alcohol consumption
and tobacco smoking was considered in the analysis. Also
speciﬁc polymorphism in genes encoding lipid transport
proteins, their receptors, and lipid-processing enzymes and
inﬂammation related proteins were shown to be associated
with the characteristic changes in blood lipid concentrations
[24–28].
One polymorphism(-504 cc) in the hepatic lipase gene is
associated with an increase in protective HDL levels compared
with the TT genotype (common in certain ethnic groups such
as African–Americans) in response to high fat diet [21].4.2.1. Hypertension
Arterial hypertension constitutes an important pathogenetic
element in CVD. It is now well understood that numerous ge-
netic factors are involved in blood pressure regulation and
some genetic patterns can be responsible for raising blood
pressure, which characterizes essential (primary) hypertension
[29]. Hypertension is one of the components of the obesity-
associated metabolic syndrome [12], and inﬂuence of dietary
factors altering energy homeostasis appears to predispose to
blood pressure elevation. It is well known that the loss of
weight in hypertensive obese individuals usually leads to simul-
taneous blood pressure decrease [30].
Sodium chloride is the only dietary risk factor well deﬁned
to predispose to hypertension. However, blood pressure re-
sponses to increases and decreases in dietary salt intake may
be heterogenous, as only about 15% have sodium-sensitive
hypertension. For the other 85%, eliminating salt from the diet
has no effect on their blood pressure [31].
Polymorphic genes implicated in blood pressure regulation
include renin-angiotensin system genes including those encod-
ing angiotensinogen (AGT), angiotensin converting enzyme
(ACE), and aldosterone synthetase (CYP11B2) [29]. However,
no evidence of the interactions between polymorphic variants
of these genes and dietary factors is available. On the other
hand sodium transport/metabolism-related genes such as those
encoding epithelial sodium channel (ENaC) subunits, adducin,
and 11B-hydroxysteroid dehydrogenase are certainly of inter-
est, given well-proven association between dietary salt intake
and hypertension [31]. There are also some reports associating
human hypertension with polymorphisms in some G-proteins
(G protein_subunit, GNAS1) and adrenergic receptors but evi-
dence is not sufﬁcient [15]. So nutrigenomics is addressing why
some people can control their hypertension with diet, whereas
others require drugs.4.2.2. Arterial thrombosis
Thrombosis of arteries affected by atherosclerosis constitutes
the main mechanism leading to acute coronary and cerebro-
vascular syndromes. Impaired balance of multiple factorsconstituting blood coagulation system can lead to hypercoag-
ulative state increasing thrombosis probability. Both the envi-
ronmental and genetic factors are involved. Diet, especially
excessive fat ingestion can trigger postprandial hypercoagula-
tive state [32]. Gene polymorphisms affecting hemostasis (as
genes encoding platelet surface glycoproteins, and coagulation
factors) have been implicated [33,34]. Blood coagulation is
counterbalanced by the anticoagulant and ﬁbrinolytic systems
that also include polymorphic factors [34].
4.2.3. Homocysteine metabolism
Hyperhomocysteinemia is now regarded as an independent
risk factor in the development of cerebrovascular and coronary
heart disease as well as venous thrombosis [35].
5. Nutrigenomics and cancer
Cancer is a process composed of multiple stages in which gene
expression, and protein and metabolite function begin to oper-
ate aberrantly [36]. In the post-genomic era, the cellular events
mediating the onset of carcinogenesis, in addition to their
modulation by dietary factors, has yielded important informa-
tion in understanding of this disease [37]. Inherited mutations
in genes can increase one’s susceptibility for cancer. The risk of
developing cancer can be markedly increased if there is a gene-
diet interaction. Studies of twins show that the likelihood of
identical twins developing the same cancer is less than 10%,
indicating that the environment plays an important role in can-
cer susceptibility [7].
Evidence of genome and epigenome damage biomarkers, in
the absence of overt exposure of genotoxins, are themselves
sensitive indicators of deﬁciency in micronutrients required
as cofactors or as components of DNA repair enzymes, for
maintenance methylation of CpG sequences and prevention
of DNA oxidation and/or uracil incorporation into DNA [38].
Diet considered as a source of either carcinogens (intrinsic
or cooking-generated) present in certain foods or constituents
acting in a protective manner (vitamins, antioxidants, detoxify-
ing enzyme-activating substances, etc.) [39]. It is clear that car-
cinogen metabolism-affecting polymorphisms may modify
probability of contact between carcinogens and target cells,
thus acting at the stage of cancer initiation [15].
Inﬂuences of polymorphisms of gene encoding factors in-
volved in hormonal regulation are most strongly manifested
in hormone dependent tumors such as breast, prostate, ovarian
and endometrial cancers. Polymorphisms in sex hormone
receptor genes comprising those encoding estrogen receptor,
progesterone receptor, and androgen receptor have been
shown to be associated with cancer risk modulation [15]. Die-
tary factors can certainly interact with hormonal regulation.
Obesity strongly affects hormonal status. At the same time
some food components, such as phytoestrogens are known
to be processed by the same metabolic pathways as sex hor-
mones [40], thus their cancer-preventive effect can be modu-
lated by the polymorphisms mentioned here.
5.1. Diet and increased risk of cancer
There are various examples of the effects of diet on cancer risk.
There is an increase risk of colorectal cancer with high con-
sumption of red meat [21]. N-Acetyl transferase (NAT) is a
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and NAT2. Several polymorphisms exist in NAT1 and
NAT2, some of which have been associated NAT capabilities
of slow, intermediate, or fast acetylations. NAT is involved in
acetylation of the heterocyclic aromatic amines found in heated
products especially well cooked red meet. During cooking of
muscle meat at high temperature some aminoacids may react
with creatinine to give heterocyclic aromatic amines (HAA).
HAA can be activated through acetylation to reactive metabo-
lites which bind DNA and cause cancers. Only NAT2 fast acet-
ylators can perform this acetylation. NAT fast acetylator
genotype had a higher risk of developing colon cancer in people
who consumed relatively large quantities of red meat [21].
A combination of excess body weight and physical inactiv-
ity are estimated to account for one ﬁfth to one third of several
of the most common cancers, speciﬁcally cancers of the breast
(postmenopausal), colon, endometrium, kidney and esophagus
(adenocarcinoma) [41].
Speciﬁc dietary irritants, such as salts and preservatives
have been suggested as being carcinogens for gastric cancer
[42].
C667T polymorphism in MTHFR gene which reduces
enzymatic activity is inversely associated with occurrence of
colorectal cancer. Low intake of folate, vitamin B12, vitamin
B6 or methonine are associated with increased risk for cancer
in CC or TT phenotype of MTHFR gene [43].
It was reported that a stronger relationship existed between
the risk of developing hepatocellular carcinoma in Sudanese
population and consumption of peanut butter with aﬂatoxins
with the glutathione S-transferase M1 null genotype compared
to those lacking the genotype [44].
5.2. Diet and cancer prevention
Cancer prevention studies have shown that all of the major
signaling pathways deregulated in different types of cancer,
are affected by nutrients. Pathways studied include: carcinogen
metabolism, DNA repair, cell proliferation/apoptosis, differen-
tiation, inﬂammation, oxidant/antioxidant balance and angio-
genesis [45]. So far, more than 1000 different phytochemicals
have been identiﬁed with cancer-preventive activities [46].
Dietary ﬁbers have a protective effect against bowel
cancer [7].
Long chain polyunsaturated fatty acids (LC-PUFA)
beneﬁcially affect physiological processes including growth,
neurological development, lean and fat mass accretion, repro-
duction, innate and acquired immunity, infectious pathologies
of viruses, bacteria and parasites; and the incidence and severity
of virtually all chronic and degenerative diseases including can-
cer, atherosclerosis, stroke, arthritis, diabetes, osteoporosis,
neurodegenerative, inﬂammatory, and skin diseases [47–51].
Fish oil, rich in omega-3 fatty acids, inhibits the growth of
colonic tumors in both invitro and invivo systems [52–54].
Bioactive components present in fruits and vegetables can
prevent carcinogenesis by several mechanisms such as blocking
metabolic activation through increasing detoxiﬁcation. Plant
foods can modulate detoxiﬁcation enzymes as ﬂavonoids, phe-
nols, isothiocyanates, allyl sulfur compounds, indoles, and
selenium [55,56]. As a result carcinogen activation, covalent
adducts with the individual nucleic acids of DNA or RNA
are formed. It has also been found that reactive oxygen species(ROS) such as superoxide anions, hydrogen peroxide, and hy-
droxyl radicals attack DNA bases, resulting in potential mis-
transcription of DNA sequence [57]. Such disruptions can
interfere with DNA replication and thus produce mutations
in oncogenes and tumor suppressor genes. ROS can also result
in breakage of DNA strand, resulting in mutations or deletions
of genetic material [58].
6. Ethical, legal and social issues in nutrigenomics
Nutrigenomics raises ethical, legal and social issues particu-
larly with respect to how the public may access nutrigenetic
tests and associated nutritional and lifestyle advice [59].
Five areas have been identiﬁed by international experts [60]
in the context of both basic nutrigenomics research and its
clinical and commercial uses: (i) health claims beneﬁts arising
from nutrigenomics, (ii) managing nutrigenomic information,
(iii) delivery methods of nutrigenomics services, (iv) nutrige-
nomics products, and (v) equitable accessibility to nutrigenom-
ics. Hence it is important to elevate the depth of depate to
understand and manage all these area.7. Conclusion
Nutrigenomics offers the potential of important health beneﬁts
for some individuals. Primary care physicians have minimal
training in nutrition and genetics, and medical geneticists are
in high demand and short supply [59]. Dietetic practitioners
are experts in nutrition science and interest in nutrigenomics
is growing among members of this professional group. How-
ever, as with physicians, dietetics practitioners would require
considerable training to bring nutrigenomics into their practice
capacity [59].
In recent years, a high-resolution recombination map of the
human genome has provided and increased the information on
the genetic order of polymorphic markers and the SNP map of
the human genome [61]. It is hoped that the map of SNPs in
the human genome will provide powerful molecular tools to
decipher the role of nutrition in human health and disease
and help deﬁning optimal diets [10]. Advanced genetic analysis
in combination with twin studies may provide opportunities to
understand the basis of complex traits and the role of individ-
ual genotypes on the development of polygenic diet-related dis-
eases such as cancer and CVS [62].
Thus nutrigenomics treats food as a major environmental
factor in the gene–environment interaction, with the ﬁnal
aim to personalize food and nutrition and ultimately individu-
alize strategies to preserve health, by tailoring the food to indi-
vidual genotype [22].References
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